JMM RESEARCH Machina Scientiae Search K Pricing
Menu
PredictionsEventsCompaniesToolsTrending stocksPeopleGuides Pricing CorrectionsTermsPrivacy

Search runs in your browser, across every published page on this site.

ROIV Pharmaceutical Preparations / ROIV, Nasdaq

Roivant Sciences Ltd. revenue $1.44M, quarter ended Jun 30, 2026

Roivant Sciences Ltd. reported $1.44M of revenue in the quarter ended Jun 30, 2026, -33.5% on the quarter ended Jun 30, 2025.

Quarterly revenue, quarter ended Jun 30, 2026 $1.44M

-33.5% year over year -$728.0K against $2.17M for the quarter ended Jun 30, 2025

Every ROIV quarter JMM stores, on a real time axis

Open SEC company facts
0.0 0.0 0.0 0.0 0.0 USD bn -33.5% year over year 0% Year over year -70.9% -63.1% +22.7% -72.8% -64.9% -33.5% 2022202320242025 Period ended Jun 30, 2026
Quarterly revenue, 8 stored SEC reporting periods, US dollars. Bars sit on a real time axis and are as wide as the period they report, so a quarter the stored set does not hold reads as a gap rather than as a step. The lower band is empty for a period whose year-ago quarter is not in the stored set.

What the ROIV record says, and what to quote from it

ROIV is smaller than it was a year ago: $1.44M against $2.17M for the quarter ended Jun 30, 2025.

The last 6 comparable prints run -70.9%, -63.1%, +22.7%, -72.8%, -64.9%, -33.5%, so the latest rate is 31.3 points above the one before it and the rate has risen at each of the last 2 steps. Read the run rather than the last print: a single quarter's rate moves on the base it is measured against, and the base is a quarter of Roivant Sciences Ltd.'s trading a year earlier, not a smooth line.

The period stored before this one ended Sep 30, 2025, about 3 quarters earlier, so a step against it would not describe a quarter of trading. SEC builds its quarterly frames from the values a filer tags, and most filers tag no standalone fourth quarter: it is reported inside the annual filing as part of the year.

These quarters do not close a fiscal year. The annual report in ROIV's filing history carries the year as Roivant Sciences Ltd. reports it.

Machine Noticed: one thing the scan flagged in the ROIV filing record

Scan of Aug 13, 2026, 01:17 UTC

  1. Roivant Sciences Ltd. revenue changed -33.5% year over year in the quarter ended Jun 30, 2026, +11.0 percentage points against the -44.5% it averaged over the 4 prior quarters this projection can compare.

    Revenue growth shift detector 1.1.0 8 records, 2 source documents

    Show the arithmetic, step by step
    StepOperationInputsResult
    yoy now change against the earlier value, in percent
    • $1,442,000value, companies
    • $2,170,000value, companies
    		-33.55%
    yoy prior1 change against the earlier value, in percent
    • $7,990,000value, companies
    • $21,624,000value, companies
    		-63.05%
    yoy prior2 change against the earlier value, in percent
    • $4,475,000value, companies
    • $3,648,000value, companies
    		+22.67%
    yoy prior3 change against the earlier value, in percent
    • $2,170,000value, companies
    • $7,990,000value, companies
    		-72.84%
    yoy prior4 change against the earlier value, in percent
    • $1,571,000value, companies
    • $4,475,000value, companies
    		-64.89%
    prior mean mean
    • -63.05%from step yoy prior1
    • 22.67%from step yoy prior2
    • -72.84%from step yoy prior3
    • -64.89%from step yoy prior4
    		-44.53%
    shift difference
    • -33.55 percentage pointsfrom step yoy now
    • -44.53 percentage pointsfrom step prior mean
    		+10.98 pp
    window quarters count
    • $7,990,000value, companies
    • $4,475,000value, companies
    • $2,170,000value, companies
    • $1,571,000value, companies
    		4 records
See everything the scan flagged today

ROIV quarterly revenue, filing by filing

All ROIV filings
Period ended Quarterly revenue Year over year Filed Evidence
10-Q $1.4M -33.5% vs $2.2M, period ended Jun 30, 2025 Open filing
10-Q $1.6M -64.9% vs $4.5M, period ended Sep 30, 2024 Open filing
10-Q $2.2M -72.8% vs $8.0M, period ended Jun 30, 2024 Open filing
10-Q $4.5M +22.7% vs $3.6M, period ended Sep 30, 2023 Open filing
10-Q $8.0M -63.1% vs $21.6M, period ended Jun 30, 2023 Open filing
10-Q $3.6M -70.9% vs $12.5M, period ended Sep 30, 2022 Open filing
10-Q $21.6M Not stored no quarter one year earlier in the stored set Open filing
10-Q $12.5M Not stored no quarter one year earlier in the stored set Open filing
Period endedJun 30, 202610-Q, filed Aug 6, 2026 Quarterly revenue$1.4M Year over year -33.5% vs $2.2M, period ended Jun 30, 2025 Open filing Period endedSep 30, 202510-Q, filed Nov 10, 2025 Quarterly revenue$1.6M Year over year -64.9% vs $4.5M, period ended Sep 30, 2024 Open filing Period endedJun 30, 202510-Q, filed Aug 6, 2026 Quarterly revenue$2.2M Year over year -72.8% vs $8.0M, period ended Jun 30, 2024 Open filing Period endedSep 30, 202410-Q, filed Nov 10, 2025 Quarterly revenue$4.5M Year over year +22.7% vs $3.6M, period ended Sep 30, 2023 Open filing Period endedJun 30, 202410-Q, filed Aug 11, 2025 Quarterly revenue$8.0M Year over year -63.1% vs $21.6M, period ended Jun 30, 2023 Open filing Period endedSep 30, 202310-Q, filed Nov 12, 2024 Quarterly revenue$3.6M Year over year -70.9% vs $12.5M, period ended Sep 30, 2022 Open filing Period endedJun 30, 202310-Q, filed Aug 9, 2024 Quarterly revenue$21.6M Year over year Not stored no quarter one year earlier in the stored set Open filing Period endedSep 30, 202210-Q, filed Nov 13, 2023 Quarterly revenue$12.5M Year over year Not stored no quarter one year earlier in the stored set Open filing

Every row is the SEC concept RevenueFromContractWithCustomerExcludingAssessedTax, read from the SEC company facts API by the JMM collector, checked Aug 10, 2026. The change column is year over year and names the exact period it was measured against, because these periods are not contiguous: a change against whichever row happens to sit below would compare quarters up to three years apart. Earlier rows carry the accession SEC attributes the value to, which can be a later filing that restated the period, so only the most recent row's 37-day gap is a reporting delay.

ROIV against every other Pharmaceutical Preparations filer JMM covers

Open the full company index

Each issuer's latest stored quarter, in USD, for every filer JMM covers under SEC SIC 2834. Fiscal calendars differ, so these periods end on different dates: the bars compare scale, not a shared quarter. Coverage is JMM's, not the classification's, so this is not the whole industry.

Continue from the Roivant Sciences Ltd. record

GuideAudit a quarterly revenue figure in SEC company facts

Reproduce any row in the table below from the raw XBRL frames, period by period.

CalculatorAnnualize the growth between any two of these quarters

Paste a starting and ending value from the table to get a compound annual rate, before and after CPI-U inflation.

GuideWhat the XBRL tag behind this figure actually measures

Why two issuers reporting the same business can carry different revenue concepts, and what that changes about comparing them.